WilmerHale Advises Underwriters in $36.4M Cerecor Inc. Offering

WilmerHale Advises Underwriters in $36.4M Cerecor Inc. Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale represented the underwriters in the public offering of 12,323,077 shares of common stock of Cerecor Inc., a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, at a public offering price per share of $2.60. In addition, and in lieu of common stock, the company offered to a certain existing investor pre-funded warrants to purchase up to an aggregate of 1,676,923 shares of common stock at a purchase price of $2.599 per pre-funded warrant. The gross proceeds to the company were $36.4 million, before deducting underwriting discounts and offering expenses. The offering priced on January 7, 2021 and closed on January 12, 2021.

The WilmerHale team advising the underwriters consisted of Lisa Firenze, Bruce Manheim, Colleen Superko, Chip McCorkle and Gerard Fischetti.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel